PY2042865A - Proceso de síntesis a escala de un inhibidor de calicreína plasmática - Google Patents

Proceso de síntesis a escala de un inhibidor de calicreína plasmática

Info

Publication number
PY2042865A
PY2042865A PY202002042865A PY2042865A PY2042865A PY 2042865 A PY2042865 A PY 2042865A PY 202002042865 A PY202002042865 A PY 202002042865A PY 2042865 A PY2042865 A PY 2042865A PY 2042865 A PY2042865 A PY 2042865A
Authority
PY
Paraguay
Prior art keywords
synthesis process
plasma kallikrein
scale synthesis
kallikrein inhibitor
inhibitor
Prior art date
Application number
PY202002042865A
Other languages
English (en)
Inventor
El-Kattan Yahya
S Babu Yarlagadda
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of PY2042865A publication Critical patent/PY2042865A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

Se divulgan métodos de preparación del Compuesto I y sales del mismo. Los métodos de preparación del Compuesto I son adecuados para usar en procesos a escala.
PY202002042865A 2019-08-06 2020-08-06 Proceso de síntesis a escala de un inhibidor de calicreína plasmática PY2042865A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962883396P 2019-08-06 2019-08-06

Publications (1)

Publication Number Publication Date
PY2042865A true PY2042865A (es) 2021-05-05

Family

ID=74504082

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202002042865A PY2042865A (es) 2019-08-06 2020-08-06 Proceso de síntesis a escala de un inhibidor de calicreína plasmática

Country Status (26)

Country Link
US (1) US12503443B2 (es)
EP (1) EP4010320A4 (es)
JP (1) JP7626751B2 (es)
KR (1) KR102928815B1 (es)
CN (1) CN114206839B (es)
AR (1) AR119617A1 (es)
AU (1) AU2020324422B2 (es)
BR (1) BR112022002060A2 (es)
CA (1) CA3149176A1 (es)
CL (2) CL2022000264A1 (es)
CO (1) CO2022002392A2 (es)
CR (1) CR20220092A (es)
DO (1) DOP2022000027A (es)
EC (1) ECSP22016209A (es)
GE (2) GEAP202515893A (es)
IL (1) IL290113B2 (es)
JO (1) JOP20220021A1 (es)
MX (1) MX2022001608A (es)
PE (1) PE20221009A1 (es)
PH (1) PH12022550221A1 (es)
PY (1) PY2042865A (es)
TN (1) TN2022000028A1 (es)
TW (1) TWI881995B (es)
UA (1) UA130182C2 (es)
UY (1) UY38826A (es)
WO (1) WO2021026182A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
EP4010320A4 (en) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Process-scale synthesis of a plasma kallikrein inhibitor
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
WO1991012779A1 (en) 1990-02-28 1991-09-05 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE60034447T2 (de) 2000-08-11 2008-02-14 Wilex Ag Nicht-kovalente Urokinase-und Angiogenese-Inhibitoren
US7038057B2 (en) 2001-08-13 2006-05-02 E.I. Du Pont De Nemours And Company Substituted 1H-dihydropyrazoles, their preparation and use
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
KR101687743B1 (ko) 2008-12-18 2016-12-19 바이엘 인텔렉쳐 프로퍼티 게엠베하 살해충제로서의 테트라졸 치환된 안트라닐산 아미드
CN102464701B (zh) 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
DK2909181T3 (da) 2012-10-16 2017-11-20 Tolero Pharmaceuticals Inc PKM2-modulatorer og fremgangsmåder til anvendelse deraf
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
EP4010320A4 (en) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Process-scale synthesis of a plasma kallikrein inhibitor

Also Published As

Publication number Publication date
AU2020324422B2 (en) 2026-02-26
JP7626751B2 (ja) 2025-02-04
TWI881995B (zh) 2025-05-01
KR20220044276A (ko) 2022-04-07
IL290113B1 (en) 2025-04-01
BR112022002060A2 (pt) 2022-06-07
GEAP202515893A (en) 2025-02-25
CO2022002392A2 (es) 2022-04-08
UA130182C2 (uk) 2025-12-10
AR119617A1 (es) 2021-12-29
WO2021026182A1 (en) 2021-02-11
EP4010320A1 (en) 2022-06-15
IL290113B2 (en) 2025-08-01
CR20220092A (es) 2022-06-03
PE20221009A1 (es) 2022-06-15
PH12022550221A1 (en) 2022-12-19
IL290113A (en) 2022-03-01
KR102928815B1 (ko) 2026-02-19
CL2022000264A1 (es) 2022-10-21
GEP20257777B (en) 2025-07-10
EP4010320A4 (en) 2023-08-16
ECSP22016209A (es) 2022-06-30
CL2023000942A1 (es) 2023-11-24
US12503443B2 (en) 2025-12-23
TW202120481A (zh) 2021-06-01
DOP2022000027A (es) 2022-05-31
JOP20220021A1 (ar) 2023-01-30
CN114206839B (zh) 2025-03-07
TN2022000028A1 (en) 2023-10-09
UY38826A (es) 2021-02-26
US20220289683A1 (en) 2022-09-15
AU2020324422A1 (en) 2022-03-17
CN114206839A (zh) 2022-03-18
CA3149176A1 (en) 2021-02-11
MX2022001608A (es) 2022-03-11
JP2022543419A (ja) 2022-10-12

Similar Documents

Publication Publication Date Title
CO2022002392A2 (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
CL2023002956A1 (es) Inhibidor de la proteasa 1 específica de ubiquitina (usp1)
CO2019010035A2 (es) Síntesis de inhibidor de mcl-1
MX2019011412A (es) Piperidinas como inhibidores de menina covalentes.
CO2020000371A2 (es) Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos
MX390906B (es) Procesos para preparar oligómeros de morfolino fosforodiamidato.
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
MX2018003318A (es) Derivado de biarilo y medicamento que contiene el mismo.
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
MX2019011730A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
PE20190376A1 (es) Combinaciones farmaceuticas para el tratamiento del cancer
CL2019001804A1 (es) Activador de nrf2.
CO2020001861A2 (es) Inhibidores de ror gamma
MX2019011517A (es) Proceso para producir analogos de anillo de arilomicina.
MX2025014306A (es) Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona
MX2020005168A (es) Formas de dosificacion que contienen un inhibidor calicreina de plasma.
CL2019000294A1 (es) Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma.
MX2021014245A (es) Procedimientos y productos intermedios para preparar un inhibidor de btk.
BR112022003186A2 (pt) Processo para preparar intermediário de inibidor de e-selectina
ECSP11010817A (es) Agentes antifúngicos
CR20160532A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
PL413865A1 (pl) Nowe pochodne endo - nitropodstawionych norbornenów i stereoselektywny sposób wytwarzania nowych pochodnych endo - nitropodstawionych norbornenów